MXPA04003156A - El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes . - Google Patents

El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .

Info

Publication number
MXPA04003156A
MXPA04003156A MXPA04003156A MXPA04003156A MXPA04003156A MX PA04003156 A MXPA04003156 A MX PA04003156A MX PA04003156 A MXPA04003156 A MX PA04003156A MX PA04003156 A MXPA04003156 A MX PA04003156A MX PA04003156 A MXPA04003156 A MX PA04003156A
Authority
MX
Mexico
Prior art keywords
immunoglobulin
subject
human immunoglobulin
disease
immunoglobulin composition
Prior art date
Application number
MXPA04003156A
Other languages
English (en)
Spanish (es)
Inventor
A Ostrem James
Original Assignee
Protein Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Therapeutics Inc filed Critical Protein Therapeutics Inc
Publication of MXPA04003156A publication Critical patent/MXPA04003156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA04003156A 2001-10-04 2002-10-04 El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes . MXPA04003156A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32704301P 2001-10-04 2001-10-04
US38096002P 2002-05-16 2002-05-16
PCT/US2002/033322 WO2003028668A2 (en) 2001-10-04 2002-10-04 Gammaglobulin treatment of immune disorders

Publications (1)

Publication Number Publication Date
MXPA04003156A true MXPA04003156A (es) 2005-01-25

Family

ID=26985697

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003156A MXPA04003156A (es) 2001-10-04 2002-10-04 El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .

Country Status (6)

Country Link
US (1) US20030099635A1 (enExample)
EP (1) EP1463527A4 (enExample)
JP (1) JP2005508338A (enExample)
CA (1) CA2462682A1 (enExample)
MX (1) MXPA04003156A (enExample)
WO (1) WO2003028668A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222141A1 (en) * 2002-03-29 2003-10-13 Repligen Corporation Ctla4 compositions in the treatment of autism
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014911A2 (en) * 2004-07-26 2006-02-09 Kossor David C Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US20060205012A1 (en) * 2004-12-09 2006-09-14 Meso Scale Technologies, Llc Diagnostic test
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2522753B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
EP2427497B1 (fr) * 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
BRPI1012082B1 (pt) 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US20130034541A1 (en) * 2010-04-23 2013-02-07 Probiotec Limited Pharmaceutical compositions
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
DK2961426T3 (da) 2013-02-26 2019-12-02 Baxalta GmbH Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
AU2014262890B2 (en) 2013-05-06 2019-01-31 Takeda Pharmaceutical Company Limited Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
US10478493B2 (en) 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients
ES2690178A1 (es) * 2017-05-18 2018-11-19 Apc Europe Slu Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5106618A (en) * 1987-07-02 1992-04-21 Stolle Research And Development Corporation Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
CA2110899C (en) * 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
JPH10212246A (ja) * 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
JP2002501616A (ja) * 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
JP2002513806A (ja) * 1998-05-07 2002-05-14 リサーチ・コーポレーション・テクノロジーズ・インク 自己免疫聴覚障害の治療のための免疫グロブリンの経口投与
CA2340884A1 (en) * 1998-08-25 2000-03-02 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002542205A (ja) * 1999-04-19 2002-12-10 リチャード ワイスバート、 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置
US6187309B1 (en) * 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders

Also Published As

Publication number Publication date
EP1463527A2 (en) 2004-10-06
JP2005508338A (ja) 2005-03-31
CA2462682A1 (en) 2003-04-10
EP1463527A4 (en) 2005-05-11
US20030099635A1 (en) 2003-05-29
WO2003028668A2 (en) 2003-04-10
WO2003028668A3 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
MXPA04003156A (es) El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .
US6187309B1 (en) Method for treatment of symptoms of central nervous system disorders
EP1363666A1 (en) Methods for treating disease states comprising administration of low levels of antibodies
US8968735B2 (en) Compositions and methods including a recombinant human MAB that promotes CNS remyelination
US20220054609A1 (en) Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US6713058B2 (en) Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6200565B1 (en) Oral administration of immunoglobulins for treating autoimmune hearing loss
AU2002348464A1 (en) Gammaglobulin treatment of immune disorders
CA2424623A1 (en) Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
HK1223839B (en) Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
IL221566A (en) A goat's preparation for human treatment for bone and nerve regrowth